Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc. (CERE): 11 pipeline candidates · ~21 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
20.7 months
D/E 1.00 · 0% dilution
Lead: Phase 2
11 candidates
N/A
N/A
A transparent, data-derived signal for Cerevel Therapeutics Holdings, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$322.4M
Quarterly Burn
$119.7M
Runway
20.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| carfentanil | Phase 1 |
| cer-1236 | Phase 1 |
| cvl-047 | Phase 1 |
| cvl-354 | Phase 1 |
| cvl-871 | Phase 2 |
| cvl-936 | Phase 1 |
| darigabat | Phase 2 |
| emraclidine | Phase 2 |
| fludarabine | Phase 1 |
| ly2795050 | Phase 1 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Cerevel Therapeutics Holdings, Inc.'s pipeline?
Cerevel Therapeutics Holdings, Inc. (CERE) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cerevel Therapeutics Holdings, Inc.'s lead drug candidate?
Cerevel Therapeutics Holdings, Inc.'s most advanced tracked candidate is carfentanil (Phase 1) for Opioid Use Disorder.
What is Cerevel Therapeutics Holdings, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cerevel Therapeutics Holdings, Inc. has approximately 20.7 months of cash runway.
Who is the CEO of Cerevel Therapeutics Holdings, Inc.?
Anthony Coles, M.D. is the chief executive officer of Cerevel Therapeutics Holdings, Inc. (CERE).
Get the full picture on Cerevel Therapeutics Holdings, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.